Randomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negative Breast Cancer

Baselga, J.; Gomez, P.; Greil, R.; Braga, S.; Climent, M.; Wardley, A.; Kaufman, B.; Stemmer, S.; Pego, A.; Chan, Arlene; Goeminne, J.; Graas, M.; Kennedy, J.; Ciruelos, E.M.; Schneeweiss, A.; Zubel, A.; Groos, J.; Melezinkova, H.; Awada, A.

Access Status

Fulltext not available

Authors

Baselga, J.

Gomez, P.

Greil, R.

Braga, S.

Climent, M.

Wardley, A.

Kaufman, B.

Stemmer, S.

Pego, A.

Chan, Arlene

Goeminne, J.

Graas, M.

Kennedy, J.

Ciruelos, E.M.

Schneeweiss, A.

Zubel, A.

Groos, J.

Melezinkova, H.

Awada, A.

Date

2013

Type

Journal Article

Metadata

Show full item record

Citation

Baselga, J. and Gomez, P. and Greil, R. and Braga, S. and Climent, M. and Wardley, A. and Kaufman, B. et al. 2013. Randomized Phase 11 Study of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Cetuximab With Cisplatin Versus Cisplatin Alone in Patients With Metastatis Triple-Negative Breast Cancer. Journal of Clinical Oncology. 31 (20): pp. 2586-2593.

Source Title

Journal of Clinical Oncology